Computational approaches for the design of peptides with anti-breast cancer properties

被引:2
|
作者
Shields, George C. [1 ,2 ]
机构
[1] Armstrong Atlantic State Univ, Deans Off, Savannah, GA 31419 USA
[2] Armstrong Atlantic State Univ, Dept Chem & Phys, Coll Sci & Technol, Savannah, GA 31419 USA
基金
美国国家科学基金会;
关键词
MOLECULAR-DYNAMICS SIMULATION; FREE-ENERGY LANDSCAPE; REPLICA EXCHANGE SIMULATIONS; GROWTH-INHIBITORY PEPTIDE; HUMAN ALPHA-FETOPROTEIN; BETA-HAIRPIN; FORCE-FIELD; FOLDING MECHANISM; ACTIVE-SITE; CENTER-DOT;
D O I
10.4155/FMC.09.13
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen receptor-positive breast cancer treatment, yet many of these cancers are intrinsically resistant to tamoxifen or acquire resistance during treatment. Therefore, scientists are searching for breast cancer drugs that have different molecular targets. Methodology: Recently, a computational approach was used to successfully design peptides that are new lead compounds against breast cancer. We used replica exchange molecular dynamics to predict the structure and dynamics of active peptides, leading to the discovery of smaller bioactive peptides. Conclusions: These analogs inhibit estrogen-dependent cell growth in a mouse uterine growth assay, a test showing reliable correlation with human breast cancer inhibition. We outline the computational methods that were tried and used along with the experimental information that led to the successful completion of this research.
引用
收藏
页码:201 / 212
页数:12
相关论文
共 50 条
  • [31] Evaluation of anti-breast cancer, anti-angiogenic and antioxidant properties of selected medicinal plants
    Kamble, Sonali S.
    Gacche, Rajesh N.
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2019, 25 : 13 - 19
  • [32] Development of her2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
    Nakajima, H.
    Mizuta, N.
    Sakaguchi, K.
    Fujiwara, I.
    Yoshimori, A.
    Takasawa, R.
    Tanuma, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
    Nakajima, Hiroo
    Mizuta, Naruhiko
    Sakaguchi, Koichi
    Fujiwara, Ikuya
    Yoshimori, Atsushi
    Takahashi, Satoshi
    Takasawa, Ryoko
    Tanuma, Sei-ichi
    BREAST CANCER, 2008, 15 (01) : 65 - 72
  • [34] Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
    Hiroo Nakajima
    Naruhiko Mizuta
    Koichi Sakaguchi
    Ikuya Fujiwara
    Atsushi Yoshimori
    Satoshi Takahashi
    Ryoko Takasawa
    Sei-ichi Tanuma
    Breast Cancer, 2008, 15 : 65 - 72
  • [35] Design and drug-like properties of new 5-methoxysalicylaldehyde based hydrazones with anti-breast cancer activity
    Nikolova-Mladenova, Boryana
    Momekov, Georgi
    Ivanov, Darvin
    Bakalova, Adriana
    JOURNAL OF APPLIED BIOMEDICINE, 2017, 15 (03) : 233 - 240
  • [36] Dihydroartemisinin-Chloro/Bromoisatin Hybrids: Design, Synthesis, and Anti-Breast Cancer Evaluation
    Ma, M.
    Yang, X. -m.
    Xu, Z.
    RUSSIAN JOURNAL OF GENERAL CHEMISTRY, 2024, 94 (03) : 652 - 659
  • [37] Aurora kinases: novel anti-breast cancer targets
    Yiliyaer
    Yusufu Maimaiti
    Oncology and Translational Medicine, 2019, 5 (01) : 43 - 48
  • [38] AFPep: an anti-breast cancer peptide that is orally active
    James A. Bennett
    Lori DeFreest
    Ikenna Anaka
    Hamid Saadati
    Sujata Balulad
    Herbert I. Jacobson
    Thomas T. Andersen
    Breast Cancer Research and Treatment, 2006, 98 : 133 - 141
  • [39] Computer modeling of some anti-breast cancer compounds
    Abdulrahman, Hadiza Lawal
    Uzairu, Adamu
    Uba, Sani
    STRUCTURAL CHEMISTRY, 2021, 32 (02) : 679 - 687
  • [40] Cardiac glycosides as potential anti-breast cancer agents
    Owens, M. B.
    Hill, A. D. K.
    Hopkins, A. M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : 14 - 14